History

2019
Sep
  • A paper on anti-fibrosis & anti-inflammatory efficacy of ONG41008 has been published on BioRxiv.
Jul
  • A anti-fibrosis substance patent for ONG41008 has been granted by USPTO (10,370,364)
Jan
  • A paper on anti-fibrosis efficacy of ONG21001 has been published on EBioMedicine jounal.
2018
Jun
  • A anti-fibrosis substance patent for ONG41008 has been granted by KIPO (10-1871166)
May
  • A revised paper on anti-fibrosis efficacy of ONG21001 has been published on BioRxiv.
Feb
  • A new anti-fibrosis substance patent application for ONG41008 has been filed on KIPO & PCT
2017
Sep
  • A new use patent for anti-fibrosis use of ONG21001 has been granted by KIPO(10-1780456)
Feb
  • The certification for a qualified venture company has been granted from a Korea government agency.
  • A paper on anti-fibrosis efficacy of ONG21001 has been published on BioRxiv.
2016
Dec
  • A certification for qualified company research institute from Korea government agency. (No. 2016115796)
Nov
  • A new use patent for ONG21001 has been file on USPTO
Sep
  • A new use patent for ONG21001 has been file on KIPO & PCT
Jul
  • A new head office & research institute have been established in Seoul
2015
Oct
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1564170)
May
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1522729)
Mar
  • A publication about osteoporosis treatment was
    highlighted by the ASBMB
2014
Aug
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1433794)
2013
Sep
  • Company founded